Komori
Muromachi Chemicals (4885) · FactIncrease in net assets, decline in equity ratioLatest Results briefing materials (2026-10-15): "Advanced"

Increase in Net Assets and Higher Equity Ratio

First written in FY2021-Q3. 15 of 21 entries say "Advanced", first in FY2021. Latest entry: 2026-10-15.

21entries
6years
5from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2021 – FY2023AdvancedFY2024-Q2 – FY2025-H12021: 320212022: 420222023: 420232024: 220242025: 120252026: 72026
Same theme, other companies
Net Asset Growth and Changes in the Equity RatioA theme 17 companies write about · 0 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2025: 4 of 17 companies on the "Worse" side.

0 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 17 companies compared. The sentences above are computed from all 17.
Full recordFilings, disclosures and news, newest first
  1. FY2026Increase in net assets, decline in equity ratioAnnual report

    「The valuation difference on other securities increased by ¥86.880 million and retained earnings increased by ¥22.782 million, among other factors. Net assets increased by ¥124.780 million from the end of the previous fiscal year to ¥2,576.562 million. As a result, the equity ratio was 40.6%.」

    Net assets increased from the end of the previous fiscal year, while the equity ratio declined from 46.6% at the end of the previous fiscal year to 40.6%.
  2. FY2026-H1Increase in net assets, decline in equity ratioAnnual report

    「Net assets at the end of the interim accounting period increased by ¥198.527 million from the end of the previous fiscal year to ¥2,650.309 million. As a result, the equity ratio was 41.0%.」

    Net assets increased from the end of the previous fiscal year, while the equity ratio declined from 46.6% at the end of the previous fiscal year to 41.0%.
  3. FY2025-H1AdvancedAnnual report

    「Net assets at the end of the interim accounting period increased by ¥51.555 million from the end of the previous fiscal year to ¥2,322.777 million. As a result, the equity ratio was 42.2%.」

    Net assets increased by ¥51.555 million from the end of the previous fiscal year. The equity ratio was disclosed as 42.2%.
  4. FY2024-Q3AdvancedAnnual report

    「Net assets at the end of the third quarter accounting period increased by ¥180.377 million from the end of the previous fiscal year to ¥2,095.606 million. As a result, the equity ratio was 39.9%.」

    Net assets increased by ¥180.377 million from the end of the previous fiscal year, and the equity ratio rose from 38.7% to 39.9%.
  5. FY2024-Q2AdvancedAnnual report

    「Net assets at the end of the second quarter accounting period increased by ¥62.350 million from the end of the previous fiscal year to ¥1,977.580 million. As a result, the equity ratio was 38.9%.」

    Net assets increased by ¥62.350 million from the end of the previous fiscal year, and the equity ratio rose from 38.7% at the end of the previous fiscal year to 38.9%.
  6. FY2024-Q1Lower net assets and higher equity ratioAnnual report

    「Net assets at the end of the first quarter accounting period decreased by ¥29.127 million from the end of the previous fiscal year to ¥1,886.101 million. As a result, the equity ratio was 39.0%.」

    Net assets decreased from the end of the previous fiscal year, while the equity ratio rose from 38.7% at the end of the previous fiscal year to 39.0%.
  7. FY2023AdvancedAnnual report

    「Retained earnings increased by ¥185.524 million and treasury shares increased by ¥59.832 million, among other factors. Net assets increased by ¥234.148 million from the end of the previous fiscal year to ¥1,915.229 million. As a result, the equity ratio was 38.7%.」

    Net assets increased by ¥234.148 million from the end of the previous fiscal year, and the equity ratio rose from 35.0% to 38.7%.
  8. FY2023-Q3AdvancedAnnual report

    「Net assets at the end of the third quarter accounting period increased by ¥190.042 million from the end of the previous fiscal year to ¥1,871.123 million. As a result, the equity ratio was 37.5%.」

    Net assets increased by ¥190.042 million from the end of the previous fiscal year, and the equity ratio rose from 35.0% to 37.5%.
  9. FY2023-Q2AdvancedAnnual report

    「Net assets at the end of the second quarter accounting period increased by ¥106.626 million from the end of the previous fiscal year to ¥1,787.706 million. As a result, the equity ratio was 35.8%.」

    Net assets increased by ¥106.626 million from the end of the previous fiscal year, and the equity ratio rose from 35.0% to 35.8%.
  10. FY2023-Q1AdvancedAnnual report

    「Net assets at the end of the first quarter accounting period increased by ¥17.679 million from the end of the previous fiscal year to ¥1,698.760 million. As a result, the equity ratio was 35.7%.」

    Net assets increased from the end of the previous fiscal year, and the equity ratio rose from 35.0% to 35.7%.
  11. FY2022AdvancedAnnual report

    「Retained earnings increased by ¥396.015 million and treasury shares decreased by ¥51.643 million, among other factors. Net assets increased by ¥347.079 million from the end of the previous fiscal year to ¥1,681.080 million. As a result, the equity ratio was 35.0%.」

    Net assets increased from ¥1,334.001 million to ¥1,681.080 million, and the equity ratio rose from 28.9% to 35.0%.
  12. FY2022-Q3AdvancedAnnual report

    「Net assets at the end of the third quarter accounting period increased by ¥266.683 million from the end of the previous fiscal year to ¥1,600.684 million. As a result, the equity ratio was 35.2%.」

    Net assets increased by ¥266.683 million from the end of the previous fiscal year, and the equity ratio rose from 34.6% to 35.2%.
  13. FY2022-Q2AdvancedAnnual report

    「Net assets at the end of the second quarter accounting period increased by ¥231.284 million from the end of the previous fiscal year to ¥1,565.285 million. As a result, the equity ratio was 34.6%.」

    Net assets increased by ¥231.284 million from the end of the previous fiscal year, and the equity ratio rose from 31.0% to 34.6%.
  14. FY2022-Q1AdvancedAnnual report

    「Net assets at the end of the first quarter accounting period increased by ¥69.451 million from the end of the previous fiscal year to ¥1,403.453 million. As a result, the equity ratio was 31.0%.」

    Net assets increased by ¥69.451 million from the end of the previous fiscal year, and the equity ratio rose from 28.9% to 31.0%.
  15. FY2021AdvancedAnnual report

    「Other capital surplus increased by ¥600.629 million, retained earnings increased by ¥180.362 million, and disposal of treasury shares contributed ¥131.138 million, among other factors. Net assets increased by ¥1,081.748 million from the end of the previous fiscal year to ¥1,334.001 million. As a result, the equity ratio was 28.9%.」

    Net assets increased by ¥1,081.748 million from the end of the previous fiscal year, and the equity ratio was 28.9%.
  16. FY2021-Q3First statedAnnual report

    「Net assets at the end of the third quarter accounting period increased by ¥850.773 million from the end of the previous fiscal year to ¥1,103.026 million. As a result, the equity ratio was 22.1%.」

    The disclosure reports the increase in net assets from the end of the previous fiscal year and the equity ratio at the end of the third quarter accounting period.
Moved together

"Results for the nine months ended in the third quarter" moved the same way as this thread, in the same document, in 15 of its 21 moves.

151111877★123456
  1. ★This thread
  2. 1Results for the nine months ended in the third quarter15×
  3. 2Steady sales of core pharmaceuticals and related products11×
  4. 3Revenue Recognition from Large-Scale Equipment Projects and Solid Sales of Chemical Products11×
  5. 4Decline in sales and operating loss in the health foods business8×
  6. 5Executive Compensation Policy Including Restricted Stock7×
  7. 6Recovery of sales in the health food business and expansion of product formats and proposal capabilities7×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Muromachi Chemicals yet. It last moved in the Results briefing materials of 2026-10-15: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Increase in Net Assets and Higher Equity Ratio | MUROMACHI CHEMICALS INC. (4885) | Komori